Combination of Deauville score and quantitative positron emission tomography parameters as a predictive tool of anti‐CD19 chimeric antigen receptor T‐cell efficacy
Sign Up to like & getrecommendations! Published in 2022 at "Cancer"
DOI: 10.1002/cncr.34532
Abstract: Autologous anti‐CD19 chimeric antigen receptor (CAR) T‐cell therapy is an effective treatment for approximately 40% of relapsed/refractory large B cell lymphomas (LBCL), and early identification of patients at risk for relapse or progression after CAR… read more here.
Keywords: cell; antigen receptor; chimeric antigen; cd19 chimeric ... See more keywords
Ruxolitinib treatment for acute gastrointestinal graft-versus-host disease caused by donor-derived CD19-Chimeric antigen receptor T-Cell infusion in a patient with B-ALL relapsed after Allo-HSCT
Sign Up to like & getrecommendations! Published in 2019 at "Regenerative Therapy"
DOI: 10.1016/j.reth.2019.06.006
Abstract: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) has remarkably improved the dismal prognosis of many aggressive hematological malignancies. However, post-transplant relapse remains a major challenge [1]. As there are limited treatment options for the patients relapsed… read more here.
Keywords: cd19 chimeric; allo hsct; treatment; relapsed allo ... See more keywords
Efficacy of anti-CD19 chimeric antigen receptor modified T(CAR-T) cell therapy in Chinese patients with relapsed/refractory acute lymphocytic leukemia in a multicenter trial.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.7028
Abstract: 7028Background: r/r B-ALL was reported as the most-threatening disease because of the low disease free survival even treatment with allogeneic hematopoietic stem cell transplantation. For overcomin... read more here.
Keywords: cd19 chimeric; antigen receptor; anti cd19; cell ... See more keywords
Investigation of the risk factors to predict cytokine release syndrome in relapsed or refractory B-cell acute lymphoblastic leukemia patients receiving IL-6 knocking down anti-CD19 chimeric antigen receptor T-cell therapy
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.922212
Abstract: CD19 chimeric antigen receptor-T (CAR-T) cell therapy has achieved remarkable results in patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). However, the cytokine release syndrome (CRS) was presented in most patients as… read more here.
Keywords: cell; antigen receptor; chimeric antigen; cell therapy ... See more keywords